These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 7131280)

  • 1. Development of a method for study of the tendency of drug products to adhere to the esophagus.
    Marvola M; Vahervuo K; Sothmann A; Marttila E; Rajaniemi M
    J Pharm Sci; 1982 Sep; 71(9):975-7. PubMed ID: 7131280
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of dosage form and formulation factors on the adherence of drugs to the esophagus.
    Marvola M; Rajaniemi M; Marttila E; Vahervuo K; Sothmann A
    J Pharm Sci; 1983 Sep; 72(9):1034-6. PubMed ID: 6631689
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of formulation on oesophageal transit.
    Channer KS; Virjee JP
    J Pharm Pharmacol; 1985 Feb; 37(2):126-9. PubMed ID: 2858546
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Esophageal transit of 6 common types of tablets and capsules].
    Hey H; Jorgensen F; Sorensen K; Hasselback H; Wanberg T
    Riv Inferm; 1985 Jun; 4(2):82-5. PubMed ID: 3933094
    [No Abstract]   [Full Text] [Related]  

  • 5. Dissolution of drugs from solid dosage forms. II. In vitro and in vivo dissolutions.
    Arayne MS; Sultana N
    J Pak Med Assoc; 1979 Oct; 29(10):218-26. PubMed ID: 117138
    [No Abstract]   [Full Text] [Related]  

  • 6. Bioequivalence of doxycycline tablets and capsules.
    Cohen RK; Grauer F; Weisenberg E
    Isr J Med Sci; 1980 Jul; 16(7):454-6. PubMed ID: 7399882
    [No Abstract]   [Full Text] [Related]  

  • 7. The in-vitro porcine adhesion model is not predictive of the esophageal transit of risedronate tablets in humans.
    McCargar L; Crail D; Dansereau R; Myers W; Lane M
    Int J Pharm; 2001 Jul; 222(2):191-7. PubMed ID: 11427349
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Drug absorption and bioavailability problems of tablets and capsules].
    Cascioli D; Petrangeli B
    Boll Chim Farm; 1978 Aug; 117(8):437-51. PubMed ID: 743388
    [No Abstract]   [Full Text] [Related]  

  • 9. Comparison of WHO and US FDA biowaiver dissolution test conditions using bioequivalent doxycycline hyclate drug products.
    Strauch S; Jantratid E; Dressman JB
    J Pharm Pharmacol; 2009 Mar; 61(3):331-7. PubMed ID: 19222905
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Comparison of absorption and excretion of doxycycline capsules and tablets (author's transl)].
    Fukaya K
    Jpn J Antibiot; 1977 Aug; 30(8):619-21. PubMed ID: 909149
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmaceutical sciences--1968. A literature review of pharmaceutics.
    Bernardo PD; Russo EJ
    J Pharm Sci; 1969 Jul; 58(7):777-812. PubMed ID: 4898312
    [No Abstract]   [Full Text] [Related]  

  • 12. Bioavailability of doxycycline from dissolved doxycycline hydrochloride tablets--comparison to solid form hydrochloride tablets and dissolved monohydrate tablets.
    Saano V; Paronen P; Peura P
    Int J Clin Pharmacol Ther Toxicol; 1990 Nov; 28(11):471-4. PubMed ID: 2272707
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oesophageal transit of six commonly used tablets and capsules.
    Hey H; Jørgensen F; Sørensen K; Hasselbalch H; Wamberg T
    Br Med J (Clin Res Ed); 1982 Dec; 285(6356):1717-9. PubMed ID: 6816343
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative in vitro study of oesophageal adhesiveness of different commercial formulations containing alendronate.
    Shakweh M; Bravo-Osuna I; Ponchel G
    Eur J Pharm Sci; 2007 Aug; 31(5):262-70. PubMed ID: 17576054
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thermostability testing and degradation profiles of doxycycline in bulk, tablets, and capsules by HPLC.
    Injac R; Djordjevic-Milic V; Srdjenovic B
    J Chromatogr Sci; 2007 Oct; 45(9):623-8. PubMed ID: 17988452
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Doxycycline, tablets or capsules?].
    Merkus FW
    Ned Tijdschr Geneeskd; 1982 Jan; 126(5):203. PubMed ID: 7057946
    [No Abstract]   [Full Text] [Related]  

  • 17. Drug-induced oesophageal disorders: pathogenesis, incidence, prevention and management.
    Jaspersen D
    Drug Saf; 2000 Mar; 22(3):237-49. PubMed ID: 10738847
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Definition of a physiologic pharmacokinetic model of cutaneous drug distribution using the isolated perfused porcine skin flap.
    Williams PL; Riviere JE
    J Pharm Sci; 1989 Jul; 78(7):550-5. PubMed ID: 2674404
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Technological and pharmacotherapeutic properties of selected drugs with modified release of diclofenac sodium].
    Kołodziejczyk MK; Kołodziejska J; Zgoda MM
    Polim Med; 2012; 42(2):121-32. PubMed ID: 23016443
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The passage time for capsules and tablets through the esophagus].
    Hey H; Sørensen K; Jørgensen FB; Hasselbalch H; Wamberg T
    Ugeskr Laeger; 1983 Aug; 145(32):2432-5. PubMed ID: 6623693
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.